Conventional CARs versus modular CARs

Area of Science:

• Immunotherapy
• Oncology
• Genetic Engineering

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in treating hematological malignancies.
• CAR T-cell therapy can cause severe adverse events, including cytokine release syndrome (CRS) and tumor lysis syndrome (TLS).
• Current CAR T-cells lack regulatory control, necessitating an emergency shutdown mechanism and on/off switching capabilities.

Purpose of the Study:

• To address the limitations of conventional CAR T-cells, particularly the lack of regulatory control and safety concerns.
• To introduce a novel modular CAR variant, the universal CAR (UniCAR) system, designed for enhanced safety and efficacy.
• To enable on/off switching of CAR T-cell activity for improved therapeutic management and targeting of tumor-associated antigens (TAAs) expressed on vital tissues.

Main Methods:

• Development of a modular CAR variant, termed the universal CAR (UniCAR) system.
• Designing UniCAR to allow for controllable on/off switching of CAR T-cell activity.
• Summarizing the development and potential of the UniCAR system to overcome limitations of existing CARs.

Main Results:

• The UniCAR system is a modular CAR variant designed to overcome limitations of conventional CARs.
• It promises to provide regulatory control over CAR T-cell activity, including an emergency shutdown.
• The system allows for repeated on/off switching, crucial for managing side effects and targeting TAAs on healthy tissues.

Conclusions:

• The universal CAR (UniCAR) system represents a significant advancement in CAR T-cell therapy development.
• UniCAR offers enhanced safety through controllable activity and an emergency shutdown mechanism.
• This system holds the potential to broaden the application of CAR T-cell therapy by managing toxicities and enabling precise targeting.